3,5-Dimethoxy-phenylacetamid | 17213-62-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-Dimethoxy-phenylacetamid
• 英文别名: 2-(3,5-Dimethoxyphenyl)acetamide
• CAS: 17213-62-6
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: GMSVYOYGGWZFNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,5-Dimethoxy-phenylacetamid 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 3,5-二甲氧基苯乙胺
  参考文献：
  名称：

  Psychopharmacological Activity of Ring- and Side Chain-Substituted β-Phenethylamines¹

  摘要：

  DOI：

  10.1021/jo01106a047
• 作为产物：
  描述：

  2-(3,5-dimethoxyphenyl)acetyl chloride 在 氨 作用下， 以 四氢呋喃 为溶剂， 生成 3,5-Dimethoxy-phenylacetamid
  参考文献：
  名称：

  Discovery and Biological Evaluation of Novel Cyanoguanidine P2X₇ Antagonists with Analgesic Activity in a Rat Model of Neuropathic Pain

  摘要：

  We disclose the design of a novel series of cyanoguanidines that are potent (IC50 similar or equal to 10-100 nM) and selective (>= 100-fold) P2X(7) receptor antagonists against the other P2 receptor subtypes such as the P2Y(2), P2X(4), and P2X(3). We also found that these P2X(7) antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED50 of 38 mu mol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X(7) receptors in neuropathic pain and therefore a potential use of P2X(7) antagonists as novel therapeutic tools for the treatment of this type of pain.

  DOI：

  10.1021/jm8015848

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Organic Compounds
  申请人：BHALAY Gurdip

  公开号：US20100130506A1

  公开（公告）日：2010-05-27

  A compound of Formula I in free or salt or solvate form, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  一种以自由形式、盐或溶剂形式存在的I式化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11的含义如规范中所示，可用于治疗对上皮钠通道阻滞有反应的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• [EN] INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS INDAZOLE COMME ANTAGONISTES DES RÉCEPTEURS CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009134666A1

  公开（公告）日：2009-11-05

  Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  揭示了吲唑烯化合物，其作为CCR1活性拮抗剂是有用的，因此可用于治疗通过CCR1活性介导或维持的多种疾病和疾病，包括自身免疫疾病，如类风湿性关节炎和多发性硬化症。还披露了包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• Palladium(II)/Lewis Acid-Catalyzed Olefination of Arylacetamides with Dioxygen
  作者：Miao Zeng、Hongwu Jiang、Kaiwen Li、Zhuqi Chen、Guochuan Yin

  DOI：10.1021/acs.joc.1c02783

  日期：2022.4.1

  as the oxidant source. This protocol tolerates with different functional groups on the substrates, and the catalytic efficiency is highly Lewis acidity-dependent on added LA, that is, a stronger LA provided a better promotional effect. The 1H NMR studies of the semireaction between the arylacetamide and the Pd(II)/Sc(III) catalyst in HOAc-d4 disclosed the formation of a palladacycle intermediate, and

  本工作介绍了以分子氧为氧化剂源的 Pd(II)/LA 催化（LA：路易斯酸）芳基乙酰胺烯化。该协议对底物上的不同官能团具有耐受性，催化效率高度依赖于添加的 LA，即更强的 LA 提供了更好的促进效果。芳基乙酰胺与 Pd(II)/Sc(III) 催化剂在 HOAc- d 4中半反应的1 H NMR 研究揭示了钯环中间体的形成，并且C-H活化步骤是可逆的，这导致了氘代芳基乙酰胺底物和钯环中间体的形成。钯环中间体和烯烃之间的进一步半反应表明，它是一个干净且比 C-H 活化步骤快得多的反应，从而揭示了 Pd(II) 催化的 C-H 活化的多种机理信息。
• 2,4,5,-trisubstituted pyrimidine derivatives
  申请人：——

  公开号：US20020099207A1

  公开（公告）日：2002-07-25

  The invention relates to compounds of the formula 1 wherein R 1 is lower alkyl, lower alkoxy, pyridinyl, pyrimidinyl, phenyl, —S-lower alkyl, —S(O) 2 -lower alkyl, —N(R)—(CH 2 ) n —N(R) 2 , —O—(CH 2 ) n —N(R) 2 , —N(R) 2 , or a cyclic tertiary amine of the group 2 which may contain one additional heteroatom, selected from N, O or S, and wherein this group may be connected with the pyrimidine ring via the linker —O(CH 2 ) n —; R 2 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R 3 /R 3 ′ is, independently from each other, hydrogen or lower alkyl; R 4 is independently from each other halogen, trifluoromethyl or lower alkoxy; R 5 is hydrogen or lower alkyl; R is, independently from each other, hydrogen or lower alkyl; X is —C(O)N(R)— or —N(R)C(O)—; Y is —O—, —S—, —SO 2 —, - or —N(R)—; n is 1,2,3 or 4; and m is 0,1 or 2; or a pharmaceutically acceptable acid addition salt thereof. The compound of the invention has affintity to the NK1 receptor and is therefore suitable in the treatment of diseases related to this recepor.

  该发明涉及具有下列结构的化合物1： 其中 R1是较低的烷基、较低的烷氧基、吡啶基、嘧啶基、苯基、—S-较低的烷基、—S(O)2-较低的烷基、—N(R)—(CH2)n—N(R)2、—O—(CH2)n—N(R)2、—N(R)2或者2组的环状三级胺，该组可能包含一个额外的异原子，选自N、O或S，且该组可以通过连接基团—O(CH2)n—与嘧啶环连接； R2是氢、较低的烷基、较低的烷氧基、卤素或三氟甲基； R3/R3'分别是氢或较低的烷基； R4是独立的卤素、三氟甲基或较低的烷氧基； R5是氢或较低的烷基； R是独立的氢或较低的烷基； X是—C(O)N(R)—或—N(R)C(O)—； Y是—O—、—S—、—SO2—或—N(R)—； n是1、2、3或4； m是0、1或2； 或其药学上可接受的酸盐。该化合物具有对NK1受体的亲和力，因此适用于治疗与该受体相关的疾病。